Lucira Health, Inc. (LHDX): Price and Financial Metrics
GET POWR RATINGS... FREE!
LHDX Stock Price Chart Interactive Chart >
LHDX Price/Volume Stats
| Current price | $1.86 | 52-week high | $11.10 |
| Prev. close | $1.72 | 52-week low | $1.36 |
| Day low | $1.69 | Volume | 41,500 |
| Day high | $1.86 | Avg. volume | 116,173 |
| 50-day MA | $2.18 | Dividend yield | N/A |
| 200-day MA | $4.77 | Market Cap | 74.15M |
Lucira Health, Inc. (LHDX) Company Bio
Lucira Health, Inc. produces and distributes medical equipment. The Company offers disposable test kits to detect DNA and RNA of infectious diseases. Lucira Health markets its products in the United States.
Latest LHDX News From Around the Web
Below are the latest news stories about Lucira Health Inc that investors may wish to consider to help them evaluate LHDX as an investment opportunity.
Lucira Health Shares Fall After Announcing Debt Facility Of $80MLucira Health Inc (NASDAQ: LHDX) has entered into a debt facility of up to million with Hercules Capital and Silicon Valley Bank. Under the term loan, Lucira received the first tranche of $30 million at closing. The Company will receive the second tranche of $20 million upon achieving certain milestones between September 1, 2022, and March 31, 2023. The third tranche of $15 million will be available before June 15, 2023, also contingent on certain milestones, while the fourth tranche of $15 mill |
Lucira Health Secures Debt Facility of Up to $80 Million from Hercules Capital and Silicon Valley BankEMERYVILLE, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. ("Lucira Health" or "Lucira") (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that on February 4, 2022, it entered into a debt facility of up to $80 million with Hercules Capital, Inc. (NYSE: HTGC) ("Hercules") and Silicon Valley Bank (NASDAQ: SIVB) ("SVB"). "This debt financing will provide Lucira l |
The past year for Lucira Health (NASDAQ:LHDX) investors has not been profitableAs every investor would know, you don't hit a homerun every time you swing. But serious investors should think long and... |
Lucira™ Health Commits 2 Million At-Home Molecular COVID-19 Test Kits on AmazonLucira Health, Inc. ("Lucira Health" or "Lucira") (Nasdaq: LHDX), a medical technology company focusing on the development and commercialization of transformative and innovative infectious disease test kits, announced more than two million Lucira™ Check-It COVID-19 tests, a rapid at-home test with PCR-quality accuracy, are available on Amazon.com. Lucira's tests are available with 1-2 day Prime delivery nationwide. |
Roche to offer 'tens of millions' of at-home Covid tests by end of monthThe rollout comes amid long lines at testing sites and President Joe Biden's promise to increase the number of tests available. |
LHDX Price Returns
| 1-mo | 0.54% |
| 3-mo | -48.62% |
| 6-mo | -78.40% |
| 1-year | -70.29% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -78.40% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...